
Merck Gets Positive EU CHMP Opinion for KEYTRUDA® Plus Padcev® in Urothelial Carcinoma
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in…












